In exchange for a three-year exemption from tariffs on drug imports and other incentives, the company based In Westchester County, New York, it committed to lowering the prices of medications it currently plans to sell to Medicaid and those it plans to sell in the future. Under this plan, it will offer its cholesterol medication, Praluent, on the website TrumpRx.gov. In this way, the company, founded in 1988, joined 16 others with which the federal government was interested in reaching agreements to make medications more accessible and thus alleviate the complex economic situation the United States has been experiencing for several months, even before declaring war on Iran. “I am pleased to announce that one of the most respected pharmaceutical companies in the world—frankly, I know it very well—is Regeneron, and it has agreed to offer its prescription drugs at most-favored-nation prices with significant discounts,” the president stated in the Oval Office. It should be noted that the drug discounts negotiated by Trump can only be applied to Medicaid patients, as those with private insurance or who Those who benefit from the Medicare program will not be able to pay less for their medications. The strategy implemented from Washington consists of convincing voters in the lead-up to the midterm elections that Republicans are finding solutions to citizens' priority problems, such as healthcare. At this point, the most important thing is to demonstrate that it is possible to pay for essential goods and services such as housing, education, and healthcare without compromising the economic stability of millions of families.

Several analysts agree that the agreements established by pharmaceutical companies with the Trump administration will not significantly impact their finances, as their profit margins will tend to be higher when the medications they manufacture are promoted on the platform created by the government to offer discounted products, while making it clear that they will have the same effectiveness as those available in the private pharmaceutical market.